Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
about
Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidationHow hyperglycemia promotes atherosclerosis: molecular mechanisms.Activity of peroxisomal enzymes, and levels of polyamines in LPA-transgenic mice on two different diets.Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complicationCurrent perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary managementDetection of AGEs as markers for carbohydrate metabolism and protein denaturationVascular Effects of Dietary Advanced Glycation End ProductsGlucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetesAdvanced glycation: an important pathological event in diabetic and age related ocular diseaseLong term running biphasically improves methylglyoxal-related metabolism, redox homeostasis and neurotrophic support within adult mouse brain cortexTwo novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteinsDFT study of the mechanism of the reaction of aminoguanidine with methylglyoxalPimagedine: a novel therapy for diabetic nephropathy.[Protein glycation as a pathological mechanism in diabetes].Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?Evolving pandemic diabetic nephropathyGreen synthesis of silver nanoparticles and characterization of their inhibitory effects on AGEs formation using biophysical techniques.[The effect of Maillard reaction products on enzyme reactions]From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.SOCS3 overexpression inhibits advanced glycation end product-induced EMT in proximal tubule epithelial cellsEffects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.Evaluation of antidiabetic, antioxidant and antiglycating activities of the Eysenhardtia polystachya.Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic ratsMass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage.Thioredoxin glycation: A novel posttranslational modification that inhibits its antioxidant and organ protective actionsAn in vitro approach to the chronological aging of skin by glycation of the collagen: the biological effect of glycation on the reconstructed skin model.A novel cellular defect in diabetes: membrane repair failure.A significant inhibitory effect on advanced glycation end product formation by catechin as the major metabolite of lotus seedpod oligomeric procyanidinsAminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice.Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy.Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor.Effects of different products of peach (Prunus persica L. Batsch) from a variety developed in southern Brazil on oxidative stress and inflammatory parameters in vitro and ex vivo.Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetesInflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathyThe maillard reaction in eye diseases.The AGE-receptor in the pathogenesis of diabetic complications.Metabolic delivery of ketone groups to sialic acid residues. Application To cell surface glycoform engineering.Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy.Advanced glycation and the immune system: stimulation, inhibition or both?
P2860
Q22000860-D36C5123-697E-40C9-91DA-9A8B96165769Q24795988-6F5CCB5A-1C12-4D64-8C2D-2CBDA7282F34Q24813990-F154B4FB-A3AB-4C02-96CD-E45E47980826Q26751110-DA314826-9CB5-4CAA-A668-8E63C2C3BBB5Q26781156-03A9BFCE-A489-4B9D-94A3-160E9AA4B0F9Q27011470-2BE957F5-8308-4B1B-8DD4-237672B41D0BQ28081090-A0C9D9D6-884D-4980-819A-ADED2DCFD462Q28304701-BB3AFFD9-9ADD-40A7-A637-9B920C16863AQ28365776-5BE84F06-3EA1-42AE-8A43-E8A050671312Q28480569-F0AC0734-0E37-4199-8666-0CBC675C6771Q28645665-AD0B45A6-BBC6-4C28-8871-891DF587683CQ30013723-10CA00B3-0026-4F0D-8CC7-940D2E32C54BQ30309168-A85EAED6-8487-40F6-8D29-2676E4FA3BCCQ30318169-5B6AE9D7-8C15-4511-AED5-DB3DA9100985Q30352122-F0415764-DD4D-4A71-BA37-9E82A99842B5Q30352538-BD594EBD-C89C-46B5-A6A3-CB79EACECAF9Q30384036-C457BEFA-F1DD-43C9-A3A3-5D7103F92EDDQ30426392-D2DE67F7-5133-44A2-871E-64D74B1979B5Q33220108-A0A92364-D9A9-4B8F-A7AD-24BF704191BBQ33744838-DEDE7839-E993-4E95-8E78-F2C80D883B31Q33746869-2092E2A7-EB73-4E51-BA15-0D7AA7C7EAD6Q33833090-AD4C8B2A-BC25-41B9-ABEF-9396EF82AFA3Q33902393-03675A4D-F43C-4C55-866E-A3F4E3EF8EAAQ33922502-F48F4F14-3898-4E53-9752-5BC741F08726Q33976920-D6A2F7C7-A135-4010-96DC-BC6324F95834Q33988813-8E1665B9-FCA8-411A-A97E-27DC038B962DQ34028243-FF1F4500-5288-448A-8C39-7CBFD8D395B3Q34091787-B5F4ADAA-BC15-4A01-974B-679E4CA6F709Q34153407-BD99E6EB-D008-42D8-9E8A-A487D0C8C3E2Q34180296-D37E3B0E-1264-4B93-BE0D-1A9644D844A7Q34218935-84B71F14-2999-4BF6-933F-050F17A3ABA3Q34248133-94C64D82-2755-4FA1-AAD7-B1926221876BQ34292383-78057BD9-E7F5-4EB8-957B-1A50CFA1F621Q34299928-D9553614-C8E1-411A-B87B-765CB62C00D3Q34388076-48B22E25-2FDF-4AEF-ABB7-CF8B63C6D0D4Q34436018-65732913-D6EA-4C10-BD90-AD14E4AEF552Q34470639-193CB031-0281-4252-A456-C8A4CC12D7DDQ34479762-50869DA0-5D0C-498D-97A1-1E03A67063F8Q34557348-E5A1AF58-28D2-46C8-879B-A398D14B95DEQ34570629-300336B5-AB12-4EA3-9CBD-9CAD92F708D7
P2860
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
description
1986 nî lūn-bûn
@nan
1986 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
name
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@ast
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@en
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@nl
type
label
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@ast
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@en
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@nl
prefLabel
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@ast
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@en
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@nl
P2093
P356
P1433
P1476
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
@en
P2093
P304
P356
10.1126/SCIENCE.3487117
P407
P577
1986-06-01T00:00:00Z